The field you can read, and the field you can reach
A good reference is exhaustive about identity. It will give you a peptide’s sequence, its receptor, the second messenger it trips, the half-life the native form is stuck with and the trick an analog uses to escape it. That is the field you can read. It is complete, it is stable, and — this is the quiet part — it is the same today as it was last quarter.
The field you can reach is a different map, and almost nobody publishes it. Of everything in a catalog, only a fraction is actually obtainable at research grade right now, in a form you’d trust, from a seller who can tell you where it came from. That fraction is the operative one — it’s the difference between reading about a molecule and being able to work with it — and it’s the one the neutral references leave blank.
Availability is a filter, not a footnote
Think of it as a funnel. Everything in the literature sits at the top. Each step down removes what you can’t actually act on — until what’s left is the short list you could hold in a vial this month.
Nothing about that narrowing is a knock on the molecules that don’t make it through. A compound can be brilliant on paper and simply not be synthesized at scale yet — that’s the frontier working exactly as it should. The point is that the last tier is information, and it’s information no spec sheet carries.
And unlike a sequence, it moves
A receptor doesn’t change. Reachability does — constantly. A candidate that lived only in clinical-trial data crosses over into research-grade powder. A supply line consolidates and a form that was scarce becomes routine. This is the same consolidation the supply chain is going through as it professionalizes under China’s 2026 drug-law reforms — and the community running protocols has always felt those shifts first.
Which is why availability reads like a frontier dispatch rather than a price tag. Watching what’s newly reachable tells you where the field’s manufacturing edge actually is this month — which is often a step ahead of where the reviews have caught up to.
What a vote moves, and what it doesn’t
Reachability usually moves quietly, one supplier at a time. In July 2026 it moved in public. Over two days the FDA’s Pharmacy Compounding Advisory Committee considered seven nominated peptides for the 503A bulk-substances list – the list that would let a licensed pharmacy compound a molecule under prescription – and recommended six of them (AJMC). Four of the six were already sitting in Category 2 of that list, the tier for substances the agency says may present significant safety risks. The agency’s own reviewers opposed every one, on the same grounds each time: the studies were short, small, and could not establish safety or effectiveness.
| Molecule | Status before | Committee vote | FDA staff | Status today |
|---|---|---|---|---|
| BPC-157 | Category 2 | Recommend · 8–6, 1 abstain | Opposed | Category 2 |
| KPV | Category 2 | Recommend · 8–6, 1 abstain | Opposed | Category 2 |
| TB-500 | Unapproved | Recommend · 8–6, 1 abstain | Opposed | Unapproved |
| MOTS-c | Category 2 | Recommend · 7–5, 2 abstain | Opposed | Category 2 |
| Epitalon | Category 2 | Recommend · 7–4, 1 abstain | Opposed | Category 2 |
| Semax | Unapproved | Recommend · 8–5, 1 abstain | Opposed | Unapproved |
| Emideltide | Not categorised | Reject · 7–6, 1 abstain | Opposed | Not categorised |
Read the table from right to left and the point makes itself. Every row still carries the status it had the morning of the vote. A recommendation from an advisory committee starts a rulemaking; it does not finish one, and the agency is not bound by it. Until notice-and-comment rulemaking concludes – a process measured in a year or more – a Category 2 substance still may not lawfully be compounded, and a never-categorised one is still research-use-only material. For the one molecule with the most to gain, the human evidence in the room was thirty uncontrolled patients.
A vote is exactly the kind of event that gets reported as a change in what you can get. It is not one. It is a change in what might be reachable through a different channel in 2027 or 2028, and the gap between those two sentences is the whole reason reachability has to be published as dated data rather than remembered as news.
How a reference publishes this without becoming a store
The obvious objection: the moment a reference tells you where to buy, hasn’t it stopped being a reference? Only if the buying decides the writing. Keep those two apart and availability becomes just another honest data field. Three rules hold the line:
- Listed is earned, not paid. a compound appears in the availability layer only when it clears a fixed sourcing standard — a lot-specific COA, primary literature cited on the page, sold research-use-only. Payment can buy a link; it can't buy a listing
- Absence claims nothing. not being listed means "not currently stocked to the standard," never "inferior." The layer only ever makes a positive statement, so it can't be used to bury a rival
- The wall is real. the commercial layer lives in its own module and the monographs can't import it. No mechanism, fact, or evidence grade can be bent by who's selling what
Do that, and the disclosure isn’t a confession — it’s the feature. Every link is marked, the one sourcing relationship is named on the methodology page, and the reader gets the one fact the rest of the internet makes them go digging for.
The highest-value fact on a reference page usually isn’t another spec — it’s whether you can act on the ones already there. Identity is settled and everywhere. Reachability is scarce, it moves, and serving it — verified, disclosed, walled off from the writing — is how a reference earns its place at the exact moment a reader has stopped reading and started deciding.
See what’s reachable now
The current availability layer — every compound verified against the sourcing standard before it earns a listing.
Open the availability indexCommon questions
Why isn't every catalogued peptide actually available?
A compound can be well characterised in the literature yet not synthesised at research grade, finished, or in stock anywhere. Being catalogued describes what is known about a molecule; availability describes whether you can obtain it right now, in a form you can trust — two different maps.
What does research-grade availability mean here?
That a molecule is currently stocked in finished, lyophilised form by a source meeting a fixed sourcing standard: a lot-specific certificate of analysis, primary literature cited on the page, and research-use-only framing. A listing is verified, never paid for.
Did the FDA approve BPC-157, KPV, TB-500, MOTS-c, epitalon or semax for compounding in July 2026?
No. On 23–24 July 2026 the Pharmacy Compounding Advisory Committee voted, by narrow margins and against the recommendation of FDA review staff, to recommend adding those six peptides to the 503A bulk-substances list; a seventh, emideltide, was rejected. The committee advises; the agency decides through notice-and-comment rulemaking, which has not begun to conclude. Until it does, the four already in Category 2 (BPC-157, KPV, MOTS-c, epitalon) still may not be compounded, and the two that were never categorised (TB-500, semax) remain unapproved research-use-only material. Nothing on the availability layer changed because of the vote.
How often does peptide availability change?
Constantly. Unlike a sequence or a receptor, reachability moves — candidates cross from clinical trials into research-grade supply, and manufacturing consolidates. That is why availability is tracked as living data rather than stated once.
Follow the thread
Educational and strategic reference on peptide availability and sourcing. The availability layer contains disclosed affiliate links to a single sourcing partner; it does not influence any monograph, mechanism, or evidence grade. Not medical advice and not an endorsement to obtain or use any compound — regulatory status varies by jurisdiction and by whether a compound is handled as an approved drug or a research reagent.